Última actualización 12 de septiembre de 2026
Key finding
Estimated treatment difference (ETD) for change in HbA1c was -0.2% (95% CI: -0.4, -0.1), confirming non-inferiority of icodec versus glargine U100 (p < 0.0001).
The ONWARDS 10 trial evaluated the switch from daily basal insulin to once-weekly insulin icodec, finding improvements in HbA1c and time in range compared to glargine U100.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The ONWARDS 10 trial evaluated the switch from daily basal insulin to once-weekly insulin icodec, finding improvements in HbA1c and time in range compared to glargine U100.
These findings are significant as they suggest that once-weekly insulin icodec could improve diabetes management for patients currently using daily insulin. Better glycemic control and reduced hypoglycaemia risk can enhance patient quality of life and adherence to treatment.
The study's sample size may limit generalizability. Potential unmeasured confounders could affect outcomes. The trial duration may not capture long-term effects.
Published in
Publication details and source links for this paper.
Julio R, Chantal M, Joshua BF, Priyanka R, Cathrine S, Alice YYC. Switching from daily basal insulin to once-weekly insulin icodec: ONWARDS 10 trial results. Diabetes, Obesity & Metabolism. 2026;28(9):7791-7801. doi:10.1111/dom.70813
HbA1c decreased by 0.2% with icodec compared to glargine (p=0.0001).
Time in range increased by 18.0% with icodec versus 12.1% with glargine (p=0.0005).
Hypoglycaemia rate was lower with icodec (0.45 episodes/year) compared to glargine (0.59 episodes/year).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Glargine U100, Once-weekly insulin icodec and Efficacy of Cognitive Behavioral Therapy (CBT) in Diabetes Management, HbA1c, Time in range.
This study contributes evidence to
Primary intervention
Glargine U100
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
6
Evidence pairs
1245
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Glargine U100 → Efficacy of Cognitive Behavioral Therapy (CBT) in Diabetes Management
Glargine U100 → Efficacy of Cognitive Behavioral Therapy (CBT) in Diabetes Management
Once-weekly insulin icodec → Efficacy of Cognitive Behavioral Therapy (CBT) in Diabetes Management
Once-weekly insulin icodec → Efficacy of Cognitive Behavioral Therapy (CBT) in Diabetes Management
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Glargine U100 and HbA1c, Glargine U100 and Efficacy of Cognitive Behavioral Therapy (CBT) in Diabetes Management.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies on Glargine U100
Contributes to Glargine U100 evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies measuring Efficacy of Cognitive Behavioral Therapy (CBT) in Diabetes Management
Measures Efficacy of Cognitive Behavioral Therapy (CBT) in Diabetes Management as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
1 results
3 results
3 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Glargine U100 may lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 78.5 | weak positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Once-weekly insulin icodec appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Once-weekly insulin icodec appears to improve time in range.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time in range
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Glargine U100 for efficacy of cognitive behavioral therapy (CBT) in diabetes management.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Efficacy of Cognitive Behavioral Therapy (CBT) in Diabetes Management
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
